Agency Information Collection Activities; Proposed Collection; Comment Request; Focus Groups as Used by the Food and Drug Administration (All Food and Drug Administration-Regulated Products), 18763-18765 [2017-08065]

Download as PDF Federal Register / Vol. 82, No. 76 / Friday, April 21, 2017 / Notices FEDERAL RESERVE SYSTEM sradovich on DSK3GMQ082PROD with NOTICES Formations of, Acquisitions by, and Mergers of Savings and Loan Holding Companies The companies listed in this notice have applied to the Board for approval, pursuant to the Home Owners’ Loan Act (12 U.S.C. 1461 et seq.) (HOLA), Regulation LL (12 CFR part 238), and Regulation MM (12 CFR part 239), and all other applicable statutes and regulations to become a savings and loan holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a savings association and nonbanking companies owned by the savings and loan holding company, including the companies listed below. The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the HOLA (12 U.S.C. 1467a(e)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 10(c)(4)(B) of the HOLA (12 U.S.C. 1467a(c)(4)(B)). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than May 15, 2017. A. Federal Reserve Bank of Philadelphia (William Spaniel, Senior Vice President), 100 North 6th Street, Philadelphia, Pennsylvania 19105– 1521. Comments can also be sent electronically to Comments.applications@phil.frb.org: 1. Ponce Bank Mutual Holding Company, Bronx, New York and PDL Community Bancorp, Bronx, New York; to become savings and loan holding companies, by acquiring 100 percent of Ponce Bank, Bronx, New York, upon the conversion of Ponce De Leon Federal Bank, from a federal mutual savings bank to a federal stock savings bank, to be called Ponce Bank, both of Bronx, New York. Board of Governors of the Federal Reserve System, April 17, 2017. Margaret M. Shanks, Deputy Secretary of the Board. FEDERAL RETIREMENT THRIFT INVESTMENT BOARD Sunshine Act; Notice of Board Member Meeting Federal Retirement Thrift Investment Board, 77 K Street NE., 10th Floor Board Room, Washington, DC 20002. FEDERAL REGISTER CITATION OF PREVIOUS ANNOUNCEMENT: 82 FR 17991. PREVIOUSLY ANNOUNCED TIME AND DATE OF THE MEETING: 8:30 a.m., April 24, 2017. CHANGES IN THE MEETING: Time: 9 a.m. Agenda Federal Retirement Thrift Investment Board Member Meeting, April 24, 2017, 9:00 a.m. (In-Person). Open Session 1. Approval of the Meeting Minutes for the March 27, 2017 Board Member Meeting 2. Monthly Reports (a) Participant Activity Report (b) Legislative Report 3. Quarterly Reports (c) Investment Performance (d) Audit Status 4. OCFO Annual Report and Budget Review 5. Internal Audit 6. Annual Financial Audit—CLA 7. DOL Presentation 8. Consolidated IT/Audit Activities Closed Session Information covered under 5 U.S.C. 552b(c)(9)(B). Adjourn CONTACT PERSON FOR MORE INFORMATION: Kimberly Weaver, Director, Office of External Affairs, (202) 942–1640. Dated: April 19, 2017. Megan Grumbine, Secretary, Federal Retirement Thrift Investment Board. [FR Doc. 2017–08261 Filed 4–19–17; 4:15 pm] BILLING CODE 6760–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Food and Drug Administration [Docket No. FDA–2010–N–0594] Agency Information Collection Activities; Proposed Collection; Comment Request; Focus Groups as Used by the Food and Drug Administration (All Food and Drug Administration-Regulated Products) [FR Doc. 2017–08053 Filed 4–20–17; 8:45 am] AGENCY: BILLING CODE 6210–01–P Food and Drug Administration, HHS. VerDate Sep<11>2014 17:30 Apr 20, 2017 Jkt 241001 PO 00000 Frm 00036 Fmt 4703 Sfmt 4703 ACTION: 18763 Notice. The Food and Drug Administration (FDA or Agency) is announcing an opportunity for public comment on the proposed collection of certain information by the Agency. Under the Paperwork Reduction Act of 1995 (PRA), Federal Agencies are required to publish notice in the Federal Register concerning each proposed collection of information, including each proposed extension of an existing collection of information, and to allow 60 days for public comment in response to the notice. This notice solicits comments on ‘‘Focus Groups as Used by the Food and Drug Administration (All FDA-Regulated Products).’’ SUMMARY: Submit either electronic or written comments on the collection of information by June 20, 2017. Late, untimely filed comments will not be considered. Electronic comments must be submitted on or before June 20, 2017. The https://www.regulations.gov electronic filing system will accept comments until midnight Eastern Time at the end of June 20, 2017. Comments received by mail/hand delivery/courier (for written/paper submissions) will be considered timely if they are postmarked or the delivery service acceptance receipt is on or before that date. ADDRESSES: You may submit comments as follows: DATES: Electronic Submissions Submit electronic comments in the following way: • Federal eRulemaking Portal: https://www.regulations.gov. Follow the instructions for submitting comments. Comments submitted electronically, including attachments, to https:// www.regulations.gov will be posted to the docket unchanged. Because your comment will be made public, you are solely responsible for ensuring that your comment does not include any confidential information that you or a third party may not wish to be posted, such as medical information, your or anyone else’s Social Security number, or confidential business information, such as a manufacturing process. Please note that if you include your name, contact information, or other information that identifies you in the body of your comments, that information will be posted on https://www.regulations.gov. • If you want to submit a comment with confidential information that you do not wish to be made available to the public, submit the comment as a written/paper submission and in the E:\FR\FM\21APN1.SGM 21APN1 18764 Federal Register / Vol. 82, No. 76 / Friday, April 21, 2017 / Notices manner detailed (see ‘‘Written/Paper Submissions’’ and ‘‘Instructions’’). Written/Paper Submissions Submit written/paper submissions as follows: • Mail/Hand delivery/Courier (for written/paper submissions): Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. • For written/paper comments submitted to the Division of Dockets Management, FDA will post your comment, as well as any attachments, except for information submitted, marked and identified, as confidential, if submitted as detailed in ‘‘Instructions.’’ Instructions: All submissions received must include the Docket No. FDA– 2010–N–0594 for ‘‘Focus Groups as Used by the Food and Drug Administration (All FDA-Regulated Products).’’ Received comments, those filed in a timely manner (see DATES), will be placed in the docket and, except for those submitted as ‘‘Confidential Submissions,’’ publicly viewable at https://www.regulations.gov or at the Division of Dockets Management between 9 a.m. and 4 p.m., Monday through Friday. • Confidential Submissions—To submit a comment with confidential information that you do not wish to be made publicly available, submit your comments only as a written/paper submission. You should submit two copies total. One copy will include the information you claim to be confidential with a heading or cover note that states ‘‘THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.’’ The Agency will review this copy, including the claimed confidential information, in its consideration of comments. The second copy, which will have the claimed confidential information redacted/blacked out, will be available for public viewing and posted on https://www.regulations.gov. Submit both copies to the Division of Dockets Management. If you do not wish your name and contact information to be made publicly available, you can provide this information on the cover sheet and not in the body of your comments and you must identify this information as ‘‘confidential.’’ Any information marked as ‘‘confidential’’ will not be disclosed except in accordance with 21 CFR 10.20 and other applicable disclosure law. For more information about FDA’s posting of comments to public dockets, see 80 FR 56469, September 18, 2015, or access the information at: https://www.gpo.gov/ fdsys/pkg/FR-2015-09-18/pdf/201523389.pdf. Docket: For access to the docket to read background documents or the electronic and written/paper comments received, go to https:// www.regulations.gov and insert the docket number, found in brackets in the heading of this document, into the ‘‘Search’’ box and follow the prompts and/or go to the Division of Dockets Management, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852. FOR FURTHER INFORMATION CONTACT: JonnaLynn Capezzuto, Office of Operations, Food and Drug Administration, Three White Flint North 10A63, 11601 Landsdown St., North Bethesda, MD 20852, 301–796– 3794. SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501–3520), Federal Agencies must obtain approval from the Office of Management and Budget (OMB) for each collection of information they conduct or sponsor. ‘‘Collection of information’’ is defined in 44 U.S.C. 3502(3) and 5 CFR 1320.3(c) and includes Agency requests or requirements that members of the public submit reports, keep records, or provide information to a third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) requires Federal Agencies to provide a 60-day notice in the Federal Register concerning each proposed collection of information before submitting the collection to OMB for approval. To comply with this requirement, FDA is publishing notice of the proposed collection of information set forth in this document. With respect to the following collection of information, FDA invites comments on these topics: (1) Whether the proposed collection of information is necessary for the proper performance of FDA’s functions, including whether the information will have practical utility; (2) the accuracy of FDA’s estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used; (3) ways to enhance the quality, utility, and clarity of the information to be collected; and (4) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques, when appropriate, and other forms of information technology. Focus Groups as Used by the Food and Drug Administration (All FDARegulated Products) OMB Control Number 0910–0497 FDA conducts focus group interviews on a variety of topics involving FDAregulated products, including drugs, biologics, devices, food, tobacco, and veterinary medicine. Focus groups provide an important role in gathering information because they allow for a more in-depth understanding of patients’ and consumers’ attitudes, beliefs, motivations, and feelings than do quantitative studies. Focus groups serve the narrowly defined need for direct and informal opinion on a specific topic and as a qualitative research tool have three major purposes: • To obtain patient and consumer information that is useful for developing variables and measures for quantitative studies, • to better understand patients’ and consumers’ attitudes and emotions in response to topics and concepts, and • to further explore findings obtained from quantitative studies. FDA will use focus group findings to test and refine their ideas, but will generally conduct further research before making important decisions such as adopting new policies and allocating or redirecting significant resources to support these policies. FDA estimates the burden of this collection of information as follows: sradovich on DSK3GMQ082PROD with NOTICES TABLE 1—ESTIMATED ANNUAL REPORTING BURDEN 1 Activity Number respondents Annual frequency per response Total annual responses Hours per response Total hours Focus Group Interviews ....................................................... 8,800 1 8,800 1.75 15,400 1 There are no capital costs or operating and maintenance costs associated with this collection of information. VerDate Sep<11>2014 17:30 Apr 20, 2017 Jkt 241001 PO 00000 Frm 00037 Fmt 4703 Sfmt 4703 E:\FR\FM\21APN1.SGM 21APN1 Federal Register / Vol. 82, No. 76 / Friday, April 21, 2017 / Notices Dated: April 17, 2017. Anna K. Abram, Deputy Commissioner for Policy, Planning, Legislation, and Analysis. [FR Doc. 2017–08065 Filed 4–20–17; 8:45 am] BILLING CODE 4164–01–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the Secretary [CFDA–93.788] Delegation of Authority to the Assistant Secretary for Mental Health and Substance Use Notice is hereby given that I have delegated to the Assistant Secretary for Mental Health and Substance Use, or his or her successor, the authorities vested in the Secretary of the Department of Health and Human Services, under Sec. 1003(a), (c), and (d) of the 21st Century Cures Act to support the Opioid Grant Program. This authority excludes the authority to promulgate regulations and to submit reports to Congress. These authorities may be re-delegated. I have ratified and affirmed any actions taken by the Acting Deputy Assistant Secretary for Mental Health and Substance Use or by any subordinates, which, in effect involved the exercise of these authorities delegated herein prior to the effective date of this delegation. This delegation was effective upon date of signature. Dated: April 13, 2017. Thomas E. Price, Secretary. [FR Doc. 2017–08050 Filed 4–20–17; 8:45 am] BILLING CODE 4162–20–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the Secretary sradovich on DSK3GMQ082PROD with NOTICES Notice of Interest Rate on Overdue Debts Section 30.18 of the Department of Health and Human Services’ claims collection regulations (45 CFR part 30) provides that the Secretary shall charge an annual rate of interest, which is determined and fixed by the Secretary of the Treasury after considering private consumer rates of interest on the date that the Department of Health and Human Services becomes entitled to recovery. The rate cannot be lower than the Department of Treasury’s current value of funds rate or the applicable rate determined from the ‘‘Schedule of Certified Interest Rates with Range of VerDate Sep<11>2014 17:30 Apr 20, 2017 Jkt 241001 Maturities’’ unless the Secretary waives interest in whole or part, or a different rate is prescribed by statute, contract, or repayment agreement. The Secretary of the Treasury may revise this rate quarterly. The Department of Health and Human Services publishes this rate in the Federal Register. The current rate of 10%, as fixed by the Secretary of the Treasury, is certified for the quarter ended March 31, 2017. This rate is based on the Interest Rates for Specific Legislation, ‘‘National Health Services Corps Scholarship Program (42 U.S.C. 254o(b)(1)(A))’’ and ‘‘National Research Service Award Program (42 U.S.C. 288(c)(4)(B)).’’ This interest rate will be applied to overdue debt until the Department of Health and Human Services publishes a revision. Dated: April 11, 2017. David C. Horn, Director, Office of Financial Policy and Reporting. [FR Doc. 2017–08046 Filed 4–20–17; 8:45 am] BILLING CODE 4150–04–P DEPARTMENT OF HEALTH AND HUMAN SERVICES Office of the Secretary Opioids were responsible for over 33,000 deaths in 2015; this alarming statistic is unacceptable. Through a sustained focus on people, patients, and partnerships, this crisis can be addressed across our nation. Last month President Trump announced the President’s Commission on Combating Drug Addiction and the Opioid Crisis. This Commission is tasked with studying the scope and effectiveness of the federal response to this crisis and providing recommendations to the President for improving it. As the Administration develops a comprehensive strategy to improve the federal response to combat opioids, the U.S. Department of Health and Human Services (HHS) must ensure the Opioid State Targeted Response grants are aligned accordingly and put to the best use possible. Given the urgency of the issue, we understand the need to release the funding for the first year of this program immediately. However, the intentions of HHS for the second year are to develop funding allocations and policies that are the most clinically sound, effective and efficient. In the interest of ensuring that these resources are applied in the best manner possible, I will be seeking input from Frm 00038 Fmt 4703 Sfmt 4703 the states/territories in the coming weeks and months. As funding from the first year is implemented and monitored, states/territories will be asked to identify best practices, lessons learned, and key strategies that can help HHS further target these funds in the subsequent year to best address this tragic issue. Dated: April 13, 2017. Thomas E. Price, Secretary. [FR Doc. 2017–08068 Filed 4–20–17; 8:45 am] BILLING CODE 4162–20–P DEPARTMENT OF HOMELAND SECURITY U.S. Citizenship and Immigration Services [OMB Control Number 1615–0008] Agency Information Collection Activities; Extension, Without Change, of a Currently Approved Collection: Discretionary Options for Designated Spouses, Parents, and Sons and Daughters of Certain Military Personnel, Veterans, and Enlistees U.S. Citizenship and Immigration Services, Department of Homeland Security. ACTION: 60-Day notice. AGENCY: Opioid State Targeted Response Grants PO 00000 18765 The Department of Homeland Security (DHS), U.S. Citizenship and Immigration (USCIS) invites the general public and other Federal agencies to comment upon this proposed extension of a currently approved collection of information. In accordance with the Paperwork Reduction Act (PRA) of 1995, the information collection notice is published in the Federal Register to obtain comments regarding the nature of the information collection, the categories of respondents, the estimated burden (i.e. the time, effort, and resources used by the respondents to respond), the estimated cost to the respondent, and the actual information collection instruments. DATES: Comments are encouraged and will be accepted for 60 days until June 20, 2017. ADDRESSES: All submissions received must include the OMB Control Number 1615–0008 in the body of the letter, the agency name and Docket ID USCIS– 2005–0024. To avoid duplicate submissions, please use only one of the following methods to submit comments: (1) Online. Submit comments via the Federal eRulemaking Portal Web site at http://www.regulations.gov under eDocket ID number USCIS–2005–0024; SUMMARY: E:\FR\FM\21APN1.SGM 21APN1

Agencies

[Federal Register Volume 82, Number 76 (Friday, April 21, 2017)]
[Notices]
[Pages 18763-18765]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2017-08065]


=======================================================================
-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. FDA-2010-N-0594]


Agency Information Collection Activities; Proposed Collection; 
Comment Request; Focus Groups as Used by the Food and Drug 
Administration (All Food and Drug Administration-Regulated Products)

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: The Food and Drug Administration (FDA or Agency) is announcing 
an opportunity for public comment on the proposed collection of certain 
information by the Agency. Under the Paperwork Reduction Act of 1995 
(PRA), Federal Agencies are required to publish notice in the Federal 
Register concerning each proposed collection of information, including 
each proposed extension of an existing collection of information, and 
to allow 60 days for public comment in response to the notice. This 
notice solicits comments on ``Focus Groups as Used by the Food and Drug 
Administration (All FDA-Regulated Products).''

DATES: Submit either electronic or written comments on the collection 
of information by June 20, 2017. Late, untimely filed comments will not 
be considered. Electronic comments must be submitted on or before June 
20, 2017. The https://www.regulations.gov electronic filing system will 
accept comments until midnight Eastern Time at the end of June 20, 
2017. Comments received by mail/hand delivery/courier (for written/
paper submissions) will be considered timely if they are postmarked or 
the delivery service acceptance receipt is on or before that date.

ADDRESSES: You may submit comments as follows:

Electronic Submissions

    Submit electronic comments in the following way:
     Federal eRulemaking Portal: https://www.regulations.gov. 
Follow the instructions for submitting comments. Comments submitted 
electronically, including attachments, to https://www.regulations.gov 
will be posted to the docket unchanged. Because your comment will be 
made public, you are solely responsible for ensuring that your comment 
does not include any confidential information that you or a third party 
may not wish to be posted, such as medical information, your or anyone 
else's Social Security number, or confidential business information, 
such as a manufacturing process. Please note that if you include your 
name, contact information, or other information that identifies you in 
the body of your comments, that information will be posted on https://www.regulations.gov.
     If you want to submit a comment with confidential 
information that you do not wish to be made available to the public, 
submit the comment as a written/paper submission and in the

[[Page 18764]]

manner detailed (see ``Written/Paper Submissions'' and 
``Instructions'').

Written/Paper Submissions

    Submit written/paper submissions as follows:
     Mail/Hand delivery/Courier (for written/paper 
submissions): Division of Dockets Management (HFA-305), Food and Drug 
Administration, 5630 Fishers Lane, Rm. 1061, Rockville, MD 20852.
     For written/paper comments submitted to the Division of 
Dockets Management, FDA will post your comment, as well as any 
attachments, except for information submitted, marked and identified, 
as confidential, if submitted as detailed in ``Instructions.''
    Instructions: All submissions received must include the Docket No. 
FDA-2010-N-0594 for ``Focus Groups as Used by the Food and Drug 
Administration (All FDA-Regulated Products).'' Received comments, those 
filed in a timely manner (see DATES), will be placed in the docket and, 
except for those submitted as ``Confidential Submissions,'' publicly 
viewable at https://www.regulations.gov or at the Division of Dockets 
Management between 9 a.m. and 4 p.m., Monday through Friday.
     Confidential Submissions--To submit a comment with 
confidential information that you do not wish to be made publicly 
available, submit your comments only as a written/paper submission. You 
should submit two copies total. One copy will include the information 
you claim to be confidential with a heading or cover note that states 
``THIS DOCUMENT CONTAINS CONFIDENTIAL INFORMATION.'' The Agency will 
review this copy, including the claimed confidential information, in 
its consideration of comments. The second copy, which will have the 
claimed confidential information redacted/blacked out, will be 
available for public viewing and posted on https://www.regulations.gov. 
Submit both copies to the Division of Dockets Management. If you do not 
wish your name and contact information to be made publicly available, 
you can provide this information on the cover sheet and not in the body 
of your comments and you must identify this information as 
``confidential.'' Any information marked as ``confidential'' will not 
be disclosed except in accordance with 21 CFR 10.20 and other 
applicable disclosure law. For more information about FDA's posting of 
comments to public dockets, see 80 FR 56469, September 18, 2015, or 
access the information at: https://www.gpo.gov/fdsys/pkg/FR-2015-09-18/pdf/2015-23389.pdf.
    Docket: For access to the docket to read background documents or 
the electronic and written/paper comments received, go to https://www.regulations.gov and insert the docket number, found in brackets in 
the heading of this document, into the ``Search'' box and follow the 
prompts and/or go to the Division of Dockets Management, 5630 Fishers 
Lane, Rm. 1061, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT: JonnaLynn Capezzuto, Office of 
Operations, Food and Drug Administration, Three White Flint North 
10A63, 11601 Landsdown St., North Bethesda, MD 20852, 301-796-3794.

SUPPLEMENTARY INFORMATION: Under the PRA (44 U.S.C. 3501-3520), Federal 
Agencies must obtain approval from the Office of Management and Budget 
(OMB) for each collection of information they conduct or sponsor. 
``Collection of information'' is defined in 44 U.S.C. 3502(3) and 5 CFR 
1320.3(c) and includes Agency requests or requirements that members of 
the public submit reports, keep records, or provide information to a 
third party. Section 3506(c)(2)(A) of the PRA (44 U.S.C. 3506(c)(2)(A)) 
requires Federal Agencies to provide a 60-day notice in the Federal 
Register concerning each proposed collection of information before 
submitting the collection to OMB for approval. To comply with this 
requirement, FDA is publishing notice of the proposed collection of 
information set forth in this document.
    With respect to the following collection of information, FDA 
invites comments on these topics: (1) Whether the proposed collection 
of information is necessary for the proper performance of FDA's 
functions, including whether the information will have practical 
utility; (2) the accuracy of FDA's estimate of the burden of the 
proposed collection of information, including the validity of the 
methodology and assumptions used; (3) ways to enhance the quality, 
utility, and clarity of the information to be collected; and (4) ways 
to minimize the burden of the collection of information on respondents, 
including through the use of automated collection techniques, when 
appropriate, and other forms of information technology.

Focus Groups as Used by the Food and Drug Administration (All FDA-
Regulated Products) OMB Control Number 0910-0497

    FDA conducts focus group interviews on a variety of topics 
involving FDA-regulated products, including drugs, biologics, devices, 
food, tobacco, and veterinary medicine.
    Focus groups provide an important role in gathering information 
because they allow for a more in-depth understanding of patients' and 
consumers' attitudes, beliefs, motivations, and feelings than do 
quantitative studies. Focus groups serve the narrowly defined need for 
direct and informal opinion on a specific topic and as a qualitative 
research tool have three major purposes:
     To obtain patient and consumer information that is useful 
for developing variables and measures for quantitative studies,
     to better understand patients' and consumers' attitudes 
and emotions in response to topics and concepts, and
     to further explore findings obtained from quantitative 
studies.
    FDA will use focus group findings to test and refine their ideas, 
but will generally conduct further research before making important 
decisions such as adopting new policies and allocating or redirecting 
significant resources to support these policies.
    FDA estimates the burden of this collection of information as 
follows:

                                                     Table 1--Estimated Annual Reporting Burden \1\
--------------------------------------------------------------------------------------------------------------------------------------------------------
                                                                                           Annual
                              Activity                                    Number       frequency per     Total annual      Hours per       Total hours
                                                                       respondents        response        responses         response
--------------------------------------------------------------------------------------------------------------------------------------------------------
Focus Group Interviews.............................................           8,800                1            8,800             1.75           15,400
--------------------------------------------------------------------------------------------------------------------------------------------------------
\1\ There are no capital costs or operating and maintenance costs associated with this collection of information.



[[Page 18765]]

    Dated: April 17, 2017.
Anna K. Abram,
Deputy Commissioner for Policy, Planning, Legislation, and Analysis.
[FR Doc. 2017-08065 Filed 4-20-17; 8:45 am]
BILLING CODE 4164-01-P